These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38001905)

  • 21. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.
    Felten R; Scher F; Sagez F; Chasset F; Arnaud L
    Drug Des Devel Ther; 2019; 13():1535-1543. PubMed ID: 31190735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An update on the management of refractory cutaneous lupus erythematosus.
    Verdelli A; Corrà A; Mariotti EB; Aimo C; Ruffo di Calabria V; Volpi W; Quintarelli L; Caproni M
    Front Med (Lausanne); 2022; 9():941003. PubMed ID: 36213629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice.
    Tanaka Y
    RMD Open; 2023 Aug; 9(3):. PubMed ID: 37597847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anifrolumab for systemic lupus erythematosus: A clinical study of Japanese patients in Kanazawa University Hospital.
    Fushida N; Horii M; Oishi K; Matsushita T
    J Dermatol; 2024 Apr; 51(4):607-611. PubMed ID: 37929294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations.
    Anderson E; Furie R
    Immunotherapy; 2020 Apr; 12(5):275-286. PubMed ID: 32237942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
    Vital EM; Merrill JT; Morand EF; Furie RA; Bruce IN; Tanaka Y; Manzi S; Kalunian KC; Kalyani RN; Streicher K; Abreu G; Tummala R
    Ann Rheum Dis; 2022 Jul; 81(7):951-961. PubMed ID: 35338035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
    Morand EF; Furie R; Tanaka Y; Bruce IN; Askanase AD; Richez C; Bae SC; Brohawn PZ; Pineda L; Berglind A; Tummala R;
    N Engl J Med; 2020 Jan; 382(3):211-221. PubMed ID: 31851795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New insights into the progression from cutaneous lupus to systemic lupus erythematosus.
    Zhou W; Wu H; Zhao M; Lu Q
    Expert Rev Clin Immunol; 2020 Aug; 16(8):829-837. PubMed ID: 32746644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus.
    Chia YL; Tummala R; Mai TH; Rouse T; Streicher K; White WI; Morand EF; Furie RA
    J Clin Pharmacol; 2022 Sep; 62(9):1094-1105. PubMed ID: 35352835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis.
    Tanaka Y; Atsumi T; Okada M; Miyamura T; Ishii T; Nishiyama S; Matsumura R; Hayashi N; Abreu G; Tummala R; Morand EF; Takeuchi T
    Mod Rheumatol; 2023 Jan; 33(1):134-144. PubMed ID: 35134970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.
    Bruce IN; van Vollenhoven RF; Psachoulia K; Lindholm C; Maho E; Tummala R
    Lupus Sci Med; 2023 Jan; 10(1):. PubMed ID: 36639192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case of Rowell syndrome with excellent improvement following anifrolumab.
    Shope C; Andrews L; Cunningham M; Connett J
    JAAD Case Rep; 2023 Jan; 31():27-30. PubMed ID: 36478979
    [No Abstract]   [Full Text] [Related]  

  • 33. Autoimmune Skin Conditions: Cutaneous Lupus Erythematosus.
    Foulke G; Helm LA; Clebak KT; Helm M
    FP Essent; 2023 Mar; 526():25-36. PubMed ID: 36913660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of cutaneous manifestations of lupus erythematosus: A systematic review.
    Fairley JL; Oon S; Saracino AM; Nikpour M
    Semin Arthritis Rheum; 2020 Feb; 50(1):95-127. PubMed ID: 31526594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
    Tanaka Y; Takeuchi T; Okada M; Ishii T; Nakajima H; Kawai S; Nagashima T; Hayashi N; Wang L; Tummala R
    Mod Rheumatol; 2020 Jan; 30(1):101-108. PubMed ID: 30793642
    [No Abstract]   [Full Text] [Related]  

  • 36. Cutaneous Lupus Erythematosus: Progress and Challenges.
    Petty AJ; Floyd L; Henderson C; Nicholas MW
    Curr Allergy Asthma Rep; 2020 Apr; 20(5):12. PubMed ID: 32248318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The differential panorama of clinical features of lupus erythematosus patients with different onset ages: a cross-sectional multicenter study from China.
    Yu Y; Jin H; Zhou S; Zhao M; Wu H; Long H; Fu S; Wu R; Yin H; Liao J; Luo S; Liu Y; Zhang Q; Zhang P; Tan Y; Huang X; Li F; Lin G; Lu Q
    Clin Rheumatol; 2023 Sep; 42(9):2353-2367. PubMed ID: 37311918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging Therapies in Cutaneous Lupus Erythematosus.
    Sprow G; Dan J; Merola JF; Werth VP
    Front Med (Lausanne); 2022; 9():968323. PubMed ID: 35899214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score.
    Braunstein I; Klein R; Okawa J; Werth VP
    Br J Dermatol; 2012 May; 166(5):971-5. PubMed ID: 22242767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenesis of cutaneous lupus erythema associated with and without systemic lupus erythema.
    Zhang YP; Wu J; Han YF; Shi ZR; Wang L
    Autoimmun Rev; 2017 Jul; 16(7):735-742. PubMed ID: 28483542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.